4//SEC Filing
BELLICUM PHARMACEUTICALS, INC 4
Accession 0001358403-17-000137
CIK 0001358403operating
Filed
Jul 11, 8:00 PM ET
Accepted
Jul 12, 4:43 PM ET
Size
5.6 KB
Accession
0001358403-17-000137
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Sale
Common Stock
2017-07-10$11.54/sh−10,000$115,400→ 138,965 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2017 by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.50 to $11.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 946 shares and 1,937 shares acquired by the Reporting Person under the Issuer's 2014 Employee Stock Purchase Plan on December 9, 2016 and June 10, 2017, respectively.
Documents
Issuer
BELLICUM PHARMACEUTICALS, INC
CIK 0001358403
Entity typeoperating
Related Parties
1- filerCIK 0001358403
Filing Metadata
- Form type
- 4
- Filed
- Jul 11, 8:00 PM ET
- Accepted
- Jul 12, 4:43 PM ET
- Size
- 5.6 KB